Announcement • Jul 29
HCW Biologics Inc. announced that it expects to receive $1.599293 million in funding HCW Biologics Inc entered into securities purchase agreement with a group of investors,including officers, directors and an existing stockholder of the Company, for a private placement to issue 618,682 units at an issue price of $2.585 for the proceeds of $1,599,292.97 on July 29, 2026. Unit consisting of (i) one share of the Company’s common stock, par value $0.0001 per share (“Common Stock”), or, in lieu thereof, one pre-funded warrant to purchase one share of Common Stock (a “Pre-Funded Warrant”), and (ii) the right to receive one common stock purchase warrant (a “Common Warrant”) to purchase one share of Common Stock upon, and subject to, stockholder approval of the issuance thereof. In connection with the Offering, the Company will issue 218,682 shares of Common Stock and 400,000 Pre Funded Warrants. Subject to stockholder approval, which the Company is obligated to seek pursuant to the terms of the Purchase Agreement, the Investors will also be entitled to receive Common Warrants to purchase up to an aggregate of 618,682 shares of Common Stock. Hing C. Wong, Ph.D., the Company’s Founder and Chief Executive Officer, Scott Garrett, a member and the Chairman of the Company’s Board of Directors, and Lee Flowers, the Company’s Senior Vice President of Business Development, participated in the Offering on the same terms and conditions as the other Investor. The closing of the Offering is expected to occur on or about July 29, 2026, subject to the satisfaction of customary closing conditions. The Pre-Funded Warrants have an exercise price of $0.0001 per share of Common Stock, are exercisable immediately and will not expire until exercised in full. The Common Warrants will have an exercise price of $2.585 per share and will expire on the five and one half (5.5) year anniversary of their issuance. Announcement • Jul 24
HCW Biologics Reaches Milestones For Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials In First Half 2027 HCW Biologics Inc. announced that it has requested a Type B (pre-IND application) meeting with the U.S. FDA to discuss the development and regulatory strategy for its investigational lead product candidate, HCW11-018b, a tetravalent T-cell engager (“TCE”) constructed with the Company's proprietary TRBC drug development platform .HCW11-018b is intended to treat solid tumors and is administered by subcutaneous injection. In preclinical studies, it has shown the ability to target tissue factor-expressing cancer cells and activate CD3-positive effector T cells, while simultaneously reducing immunosuppression in the tumor microenvironment. Immunosuppression in the tumor microenvironment can limit effector T-cell infiltration and antitumor activity in solid tumors, particularly in gynecologic and pancreatic cancers. TCEs have emerged as a potent therapeutic modality to treat cancer. First-generation TCEs represented a breakthrough in immunotherapy but they continue to face significant challenges, including antigen selection, limited efficacy in solid tumors, tolerability and safety concerns, and require a complex manufacturing process. Extensive preclinical studies of HCW11-018b --including assessments of in vitro and in vivo potency, antigen specificity, pharmacokinetics, toxicity in nonhuman primates, and its therapeutic window -- suggest that it may be able to overcome the limitations of earlier-generation TCEs. Currently, the U.S. FDA and other regulatory agencies have approved eight TCEs to be used to treat 12 indications. Even with a very limited number of approved indications, approved TCEs generate multi-billion-dollar annual sales. The level of interest for this area from major pharmaceutical companies remains strong over many years, as indicated by the large number of high-value partnerships formed with innovative biotechnology companies developing second-generation TCEs. These partnerships have likely been driven by TCE's potential in both oncology and autoimmune diseases. HCW11-108b is designed to treat a wide spectrum of solid tumors with enhanced anti-tumor activities and tolerability. HCW Biologics has identified HCW11-018b as the lead candidate in its Tetravalent T-Cell Engager Program, known as the“Big BiTE. Announcement • Jul 01
HCW Biologics Inc. Announces Regained Compliance with Bid Price Rule On June 29, 2026, HCW Biologics Inc. (the Company) received written notice form the Listing Qualifications Staff (the Staff) of the Nasdaq Capital Market Nasdaq Stock Market LLC (Nasdaq) that the Nasdaq Hearings Panel (the Panel) found that the Company regained compliance with Listing Rule 5550(a)(2), the Bid Price Rule, per the terms set forth in the Panel's decision letter dated May 29, 2026, as amended. As indicated in the Panel's decision letter, as amended, if the Company satisfies the remaining terms of the decision through September 22, 2026, the Panel also intends to impose a Discretionary Panel Monitor on the Company pursuant to Listing Rule 5815(d)(4)(A) for a one-year period from that date. In application of Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor until June 17, 2027. If, within that one-year monitoring period, Staff finds the Company again out of compliance with the Bid Price Rule, which was the subject of the exception, then notwithstanding Rule 5810(c)(2) the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, Staff will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable. The Company will have the opportunity to respond/present to the Hearings Panel as provided by Listing Rule 5815(d)(4)(C). The Company's securities may be at that time delisted from Nasdaq. To ensure long-term compliance with the Bid Price Rule, the Company will effect a reverse stock split at a one-for-six ratio on June 30, 2026. 
